Drug Trial Radar · NCT01126437
Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
Last checked: Nov 20, 2026Latest source record: Jun 20, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
17,183
Actual
Start
May 2010
Primary completion
May 2013
Study completion May 2013
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- May 19, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Direct comparison studies of the tiotropium HandiHaler® 18 µg and Respimat® 5 µg formulations have been limited to 4-week crossover studies. Therefore, prospective data from a trial of adequate size and duration is required to establish that compared to tiotropium HandiHaler®, tiotropium Respimat® will have (a) similar effects on safety and (b) similar or superior effects on exacerbations.
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium 18 mcgDrug
HandiHaler
tiotropium 1.25 mcg (2 actuations/day)Drug
soft mist inhaler 2 actuations=2 puffs/day
tiotropium 2.5 mcg (2 actuations/day)Drug
soft mist inhaler (2 actuations=2 puffs/day)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to All-Cause MortalityTime frame: Up to 3 years
- Time to First COPD ExacerbationTime frame: Up to 3 years
Locations
1,191 sites in 51 countries. Site status is shown where the registry gives one.
205.452.01107 Boehringer Ingelheim Investigational Site
Athens, Alabama
205.452.01023 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
205.452.01035 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
205.452.01052 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
205.452.01219 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
205.452.01227 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
205.452.01280 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
205.452.01198 Boehringer Ingelheim Investigational Site
Florence, Alabama
205.452.01244 Boehringer Ingelheim Investigational Site
Mobile, Alabama
205.452.01041 Boehringer Ingelheim Investigational Site
Montgomery, Alabama
205.452.01070 Boehringer Ingelheim Investigational Site
Anchorage, Alaska
205.452.01218 Boehringer Ingelheim Investigational Site
Chandler, Arizona
205.452.01175 Boehringer Ingelheim Investigational Site
Mesa, Arizona
205.452.01200 Boehringer Ingelheim Investigational Site
Mesa, Arizona
205.452.01317 Boehringer Ingelheim Investigational Site
Mesa, Arizona
205.452.01350 Boehringer Ingelheim Investigational Site
Pheonix, Arizona
205.452.01254 Boehringer Ingelheim Investigational Site
Phoenix, Arizona
205.452.01283 Boehringer Ingelheim Investigational Site
Phoenix, Arizona
205.452.01315 Boehringer Ingelheim Investigational Site
Tempe, Arizona
205.452.01158 Boehringer Ingelheim Investigational Site
Tucson, Arizona
205.452.01161 Boehringer Ingelheim Investigational Site
Tucson, Arizona
205.452.01302 Boehringer Ingelheim Investigational Site
Anaheim, California
205.452.01038 Boehringer Ingelheim Investigational Site
Encinitas, California
205.452.01313 Boehringer Ingelheim Investigational Site
Fountain Valley, California
205.452.01375 Boehringer Ingelheim Investigational Site
Fountain Valley, California
205.452.01074 Boehringer Ingelheim Investigational Site
Fullerton, California
205.452.01345 Boehringer Ingelheim Investigational Site
Lancaster, California
205.452.01171 Boehringer Ingelheim Investigational Site
Lincoln, California
205.452.01339 Boehringer Ingelheim Investigational Site
Lomita, California
205.452.01298 Boehringer Ingelheim Investigational Site
Los Angeles, California
205.452.01356 Boehringer Ingelheim Investigational Site
Los Angeles, California
205.452.01148 Boehringer Ingelheim Investigational Site
Orange, California
205.452.01111 Boehringer Ingelheim Investigational Site
Palm Springs, California
205.452.01147 Boehringer Ingelheim Investigational Site
Paramount, California
205.452.01071 Boehringer Ingelheim Investigational Site
Poway, California
205.452.01089 Boehringer Ingelheim Investigational Site
Rancho Cucamonga, California
205.452.01097 Boehringer Ingelheim Investigational Site
Redlands, California
205.452.01078 Boehringer Ingelheim Investigational Site
San Diego, California
205.452.01176 Boehringer Ingelheim Investigational Site
San Diego, California
205.452.01346 Boehringer Ingelheim Investigational Site
San Diego, California
Showing 40 of 1,191 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.